PLK1 and gastric cancer: Poor prognosis in GC patients related with high expressions of cyclins [50].CCNA2 is a novel predictive biomarker of sensitivity to PLK1 inhibitors for the treatment of advanced gastric cancer [51], whose overexpression was an indicator of poor prognosis.